{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-073937","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.812693+00:00","generated_at":"2026-05-17T15:16:12.249197+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protara Q2 net loss $15M; cash $145.6M into mid-2027; key trial readouts set","bullets":["Q2 2025 net loss $15.0M ($0.35/shr) vs $9.5M ($0.45/shr) in Q2 2024; R&D spend up to $10.8M.","Cash, equivalents and investments $145.6M at June 30, expected to fund operations into mid-2027.","Interim data from ~25 BCG-unresponsive NMIBC patients (ADVANCED-2 trial) expected at 1Q 2026 medical conference.","First patient in THRIVE-3 Phase 3 registrational trial of IV Choline Chloride on track for 3Q 2025.","Appointed William Conkling as Chief Commercial Officer in June 2025; added to Russell 3000 Index."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-073937","json":"https://secwatch.observer/filing/0001213900-25-073937.json","markdown":"https://secwatch.observer/filing/0001213900-25-073937.md","text":"https://secwatch.observer/filing/0001213900-25-073937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390025073937/0001213900-25-073937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390025073937/ea0250509-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:16:12.249197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}